Page 4 - Treating Fields News Today

Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with... | June 6, 2023

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for... | June 6, 2023

Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with

Shares of NovoCure Ltd. (NVCR) are slipping over 28% on Tuesday morning despite the company and Zai Lab (ZLAB) announcing that LUNAR study meets primary endpoint.

SHANGHAI and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the...

Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society

Novocure today announced 27 presentations on Tumor Treating Fields will be delivered at the American Association for Cancer Research Annual Meeting 2023, to be held April 14 to 19 in Orlando,... | April 14, 2023

Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer

Final data from the METIS study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating

Optune is now available as a treatment for newly diagnosed glioblastoma patients in France Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide